Clinical Effects of Polymyxin B in Patients infected with Carbapenem-resistant organisms

Guo-Hua Li
Second Xiangya Hospital

Qiong Lu
Second Xiangya Hospital

Qiang Qu
Second Xiangya Hospital

Hai-Hong Zhu
Second Xiangya Hospital

Hang Li
Second Xiangya Hospital

Zhan-Bo Ou-Yang
Second Xiangya Hospital

Wen-Qiang Wu
Second Xiangya Hospital

Jiao-Jiao Wang
Second Xiangya Hospital

Ting-Ting Qi
Second Xiangya Hospital

Han Yan
Second Xiangya Hospital

Hai-Yan Yuan
Second Xiangya Hospital

Jian Qu (qujianstanley@csu.edu.cn)
Second Xiangya Hospital

DOI: https://doi.org/10.21203/rs.3.rs-90880/v1
Abstract

**Purpose:** Carbapenem-resistant organisms (CROs) pose great challenges for clinical treatment. Polymyxin B (PMB) is one of the “last resort” choices of CRO infections. We explored the possible factors affecting PMB efficacy.

**Methods:** This retrospective study involved CRO infected patients treated with PMB for ≥ 72 h. The endpoint indicator was clinical efficacy. We compared the characteristics (demographics, pathogenic bacteria, PMB treatment) between patients who had “clinical success” (CS) and “clinical failure” (CF).

**Results:** A total of 192 patients were enrolled: 110 in the CS group and 82 in the CF group. The total cumulative dose for the CS group was higher than the CF group [1100 (700–1443.75) vs. 800 (500–1112.5) mg; \( P = 0.001 \)]. Treatment duration in the CS group was longer than the CF group [11 (8–14) vs. 8 (6–11) days; \( P < 0.000 \)]. Multivariate logistic regression analysis showed mechanical ventilation, vasoactive agents, multiple-site infection, and total cumulative dose to be independently associated with clinical efficacy. Cox survival analysis for 30-day mortality also showed that the use of vasoactive agents and the total cumulative dose of PMB could influence survival time and mortality rate independently.

**Conclusion:** PMB had good efficacy and a low prevalence of adverse reactions. The total cumulative dose/duration of PMB treatment, mechanical ventilation, vasoactive agents, and multiple-site infection were factors associated with the clinical efficacy of PMB.

1. **Introduction**

Carbapenem-resistant organisms (CROs) are Gram-negative bacteria that are resistant to carbapenem antibiotics. The main species of CROs are Enterobacteriaceae-resistant organisms (CREs), *Acinetobacter baumannii*-resistant organisms, and *Pseudomonas aeruginosa*-resistant organisms.[1] Due to limited treatment options and frequently a poor prognosis, CROs pose considerable challenges for clinical treatment. Therefore, research on treatment of CRO infections has attracted widespread attention. Drugs reported to be efficacious in treating CROs include colistin, aminoglycosides, tigecycline, fosfomycin, ceftazidime/avibactam, and ceftolozane/tazobactam, and combination therapy can be superior to monotherapy.[2]

Polymyxin B (PMB) is a type of polypeptide antibiotic discovered in 1947.[3] Polymyxins have strong antibacterial activity against most Gram-negative bacteria, but their clinical use has been restricted due to side effects, such as neurotoxicity and nephrotoxicity. Along with the emergence of multidrug-resistant Gram-negative bacteria, PMB and colistin have attained renewed attention because of their specific effects. Studies have shown that PMB has lower nephrotoxicity compared with colistin at recommended doses.[4–6] Therefore, PMB has been used as a first-line agent for CRO infections since it was listed in mainland China.
Studies on the pharmacokinetics, pharmacodynamics, and medications of PMB have been deepening gradually.[7] Related studies have demonstrated the efficacy, toxicity, and efficacy prediction of PMB in the treatment of CRO infections. Early treatment with PMB [8] and sound renal function [9] usually lead to better outcomes. However, PMB may have an inferior microbiologic clearance rate of carbapenem-resistant \textit{Klebsiella pneumoniae} (CRKP) compared with aminoglycoside.[10]

Although PMB is used widely clinically, several factors affecting efficacy and side effects must be explored in real-world scenarios. Therefore, we conducted a retrospective study on the administration, factors affecting efficacy, and adverse effects of PMB to provide a reference for the rational use of PMB.

2. Patients And Methods

2.1 Ethical approval of the study protocol

The study protocol was approved by the Ethics Committees of the Second Xiangya Hospital of Central South University (LYF-2020021) in Changsha, China. It was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Patients gave their written informed consent to have their data included in this study.

2.2 Patients

This retrospective study involved patients admitted to the Second Xiangya Hospital of Central South University from 2018 to 2019. The inclusion criteria were patients: (i) with a medication history of PMB (Shanghai Number 1 Biochemical & Pharmaceuticals, Shanghai, China); (ii) infected with a CRO according to bacterial-culture results; (iii) with complete medical data and basic information. The exclusion criteria were: (i) PMB administration < 72 h; (ii) patients with severe liver/kidney dysfunction or a malignant tumor before PMB treatment.

After selecting patients based on inclusion and exclusion criteria, patients were divided into two groups according to treatment results.

2.3 Collection of clinical data

Collection of clinical data was based on medical records. We collected data on: basic demographic characteristics; diagnoses; infection sites; pathogenic bacteria (and their sensitivity); Acute Physiology and Chronic Health Evaluation (APACHE) II score; medication regimens (PMB and drugs it was combined with); treatment duration; parameters of efficacy evaluation; treatment results; adverse effects.

2.4 Definitions

Patients were divided into “clinical success (CS)” and “clinical failure (CF)” groups according to efficacy. “CS” was defined as improvements and disappearances of microbiologic and clinical symptoms and parameters including body temperature, biochemistry indicators of infection, culture results and clinician documented improvements. “CF” was defined as failure to meet all the criteria for CS and
deterioration/persistence of symptoms or death.[9, 11, 12]. “Adverse effects” were defined as harmful reactions to PMB unrelated to the purpose of treatment which emerged after using the drug and disappeared when its use was stopped, including nerve–muscle blockade, nephrotoxicity, or skin pigmentation. Nephrotoxicity was based on the risk, injury, failure, loss of kidney function, and end-stage kidney disease (RIFLE) criteria.[13]

2.5 Microbiology

Testing for drug sensitivity was done by laboratory physicians using analytical instruments by the broth-microdilution method. The minimum inhibitory concentration (MIC) was determined by a VITEK®2 system (bioMérieux, Marcy-l’Étoile, France) based on recommendations of the Clinical and Laboratory Standards Institute (Beijing, China). “Carbapenem resistance” was defined as the MIC of imipenem and meropenem ≥ 4 mg/L. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST, v8.0, 2018), bacteria were resistant to tigecycline and colistin if their MIC was > 2 mg/L, respectively.[14]

2.6 Statistical analyses

Statistical analyses were undertaken using SPSS v21.0 (IBM, Armonk, NY, USA). Count data were analyzed by the chi-square test. Data with a normal distribution are expressed as the mean ± standard deviation, and were analyzed by the independent *t*-test. Data with a non-normal distribution are expressed by the median value and interquartile range, and were analyzed by the nonparametric test. Multivariate logistic regression was used to assess for the independent predictors of the clinical efficacy of PMB. Factors entered into the multivariate logistic model included any baseline differences between CS and CF groups that had *P* < 0.1 on bivariate analysis. *P* < 0.05 was considered significant. Moreover, those variables were included in the Cox model for 30-day mortality, *P* < 0.05 was considered significant.

3. Results

3.1. Characteristics

A total of 273 patients administered PMB were found in the database of the Second Xiangya Hospital of Central South University between 2018 and 2019. According to the inclusion and exclusion criteria, 192 patients were included in statistical analyses and most patients came from the “Intensive Care Unit” (59.4%).

The overall information for patients, including basic information, diagnostic information, and microbial infections, is listed in Table 1. Among all patients, 61.4% had a single-site infection and, in 56% of cases, the infection site was the respiratory tract. Also, 210 CRO strains were isolated from 192 patients. The highest proportion of pathogenic bacteria was *Acinetobacter baumannii* (63.0%), followed by *Klebsiella pneumoniae* (25.5%), *Pseudomonas aeruginosa* (17.2%), *Escherichia coli* and *Enterobacter cloacae* (3.6%). Testing for antimicrobial susceptibility showed that 15.0% of strains had a tigecycline MIC > 2 mg/L, and no strains had colistin MIC > 2 mg/L.
Table 1
Demographics and clinical characteristics of the study cohort

| Characteristic                  | Patients | (N = 192) |
|--------------------------------|----------|-----------|
| Age                            | 55.0 ± 20.2 |
| Sex                            |           |           |
| Male                           | 140 (72.9%) |
| Female                         | 52 (27.1%) |
| Weight (kg)                    | 60.0 (50.0–60.0) |
| APACHE II score                | 19.0 (12.0–24.2) |
| Mechanical ventilation         | 131 (68.2%) |
| Vasoactive agents              | 101 (52.6%) |
| Infection site                 |           |           |
| Multiple                       | 74 (38.5%) |
| Single                         | 118 (61.4%) |
| Source of infection            |           |           |
| Respiratory tract              | 170 (88.5%) |
| Blood                          | 27 (23.4%) |
| Intracranial                   | 10 (5.2%) |
| Urinary tract                  | 13 (6.8%) |
| Digestive tract                | 4 (2.1%) |
| Abdomen                        | 23 (12.0%) |
| Skin/soft tissue               | 3 (1.6%) |
| Underlying disease             |           |           |
| Pulmonary disease              | 140 (72.9%) |
| Hypertension                   | 54 (28.1%) |
| Diabetes mellitus              | 27 (14.1%) |
| Recent surgery                 | 17 (8.8%) |
| Nervous system                 | 58 (30.2%) |

Data are reported as numbers (%) or median value (interquartile ranges [IQR]), as appropriate.
| Characteristic                                      | Patients (N = 192) |
|---------------------------------------------------|--------------------|
| Pathogenic bacteria (N = 210)                     |                    |
| *Acinetobacter baumannii*                         | 121 (63.0%)        |
| *Klebsiella pneumoniae*                           | 49 (25.5%)         |
| *Pseudomonas aeruginosa*                          | 33 (17.2%)         |
| *Escherichia coli or Enterobacter cloacae*         | 7 (3.6%)           |
| Antimicrobial susceptibility                      |                    |
| Tigecycline MIC > 2 (mg/L)                        | 24/160 (15.0%)     |
| Colistin MIC > 2 (mg/L)                           | 0/210 (0.0%)       |
| Data are reported as numbers (%) or median value (interquartile ranges [IQR]), as appropriate. |        |

### 3.2. Medications and outcomes

All patients used PMB (Shanghai Number 1 Biochemical & Pharmaceuticals) according to manufacturer instructions and International Consensus Guidelines for the Optimal Use of the Polymyxins [15]. Almost all patients included in statistical analyses were administered PMB by intravenous drip (99.5%) (Table 2). We found that 35.9% of patients were given a loading dose of 50.0–100.0 mg. The dose per kilogram (mg/kg/q12h) was 0.86 (range, 0.82–1.00). Treatment duration was 10.0 (range, 7.0–13.5) days. PMB combined with another drug was given to 91.1% of cases. Meropenem was the agent combined most commonly with PMB (32.8%), followed by tigecycline (32.8%), and cefoperazone/sulbactam (27.6%).
Table 2
Regimens and outcomes

| Treatment                                             | Value                        |
|-------------------------------------------------------|------------------------------|
| Total daily dose of PMB (mg)                          | 100.0 (100.0–100.0)          |
| Loading dose (N, %)                                   | 69 (35.9%)                   |
| Loading dose (mg)                                     | 50.0 (50.0–100.0)            |
| Maintenance dose (mg)                                 | 50.0 (50.0–50.0)             |
| Total cumulative dose (mg)                            | 950.0 (650.0–1350.0)         |
| Dose per kg (mg/kg/q12h)                              | 0.86 (0.82–1.00)             |
| Administration (N, %)                                 |                              |
| Intravenous drip                                      | 191 (99.5%)                  |
| Intrathecal injection                                 | 5 (2.6%)                     |
| Injection                                             | 1 (0.5%)                     |
| Inhalation                                            | 8 (4.2%)                     |
| Start of PMB treatment after CRO confirmed (days)     | 1.0 (0.0–4.0)                |
| Treatment duration (days)                             | 10.0 (7.0–13.5)              |
| Combination                                           |                              |
| Alone                                                 | 17 (8.9%)                    |
| Meropenem                                             | 64 (33.3%)                   |
| Tigecycline                                           | 63 (32.8%)                   |
| Cefoperazone/sulbactam                                | 53 (27.6%)                   |
| Outcome                                               | Value                        |
| 30-day mortality rate                                 | 29 (15.1%)                   |
| Duration of hospitalization, median (IQR), days       | 34.0 (21.0–56.8)             |
| Bacteria elimination                                  | 46 (24.0%)                   |
| Time needed to clear bacteremia (days)                | 8.0 (6.0–13.0)               |

Data are reported as numbers (%) or median values (interquartile ranges [IQR]), as appropriate.

There were 110 patients in the CS group and 82 patients in the CF group. PMB was clinically efficacious in 57.3% of cases. The prevalence of all-cause in-hospital mortality was 14.6%. Bacteria elimination was
successful in 24.0% of cases, and the time required to clear bacteremia was 8.0 (range, 6.0–13.0) days. Duration of hospitalization was 34.0 (range, 21.0–56.8) days.

3.3 Factors related to the clinical efficacy of PMB

To explore the factors that affected the clinical efficacy of PMB, we compared all the demographics, clinical characteristics, and details of PMB treatment (dose, loading dose, timing of medication, combined medication, treatment duration) between the two groups. There was no significant difference in the time for starting PMB treatment after CROs infection confirmation (1.0 vs. 1.5 days, P = 0.761). Meanwhile, statistical difference in the combination rate of commonly used drugs did not exist in CF and CS groups (Table 3). The median total cumulative dose of patients in the CS group tended to be higher (1100 vs. 800 mg, P = 0.001) and median treatment duration was longer (11 vs. 8 days, P = 0.000). More patients in the CF group had mechanical ventilation and vasoactive agents (P ≤ 0.001). The clinical effect for patients with multiple-site infections was worse compared with that for patients with a single-site infection (29.1% vs. 70.9%, P = 0.002) (Table 3). The Mantel–Haenszel chi-square test revealed a linear association between treatment duration (P = 0.003) and total cumulative dose (P = 0.005), which correlated with CS (Fig. 1). The most common combination drugs include meropenem, tigecycline and Cefoperazone/sulbactam. However, no significant differences were found for the mode of administration and drug combination.
Table 3
Clinical characteristics of patients in the CS group and CF group after PMB treatment

| Parameters               | Success (N = 110) | Failure (N = 82) | P     |
|-------------------------|-------------------|-----------------|-------|
| Age                     | 53.3 ± 18.4       | 57.3 ± 22.3     | 0.187 |
| Sex (male)              | 84 (76.4%)        | 56 (68.3%)      | 0.213 |
| APACHE II score         | 19.0 (13.2–24.0)  | 19.0 (11.0–26.5)| 0.878 |
| Mechanical ventilation  | 60 (54.5%)        | 71 (86.6%)      | <0.001|
| Vasoactive agents       | 41 (37.3%)        | 60 (73.2%)      | <0.001|

Infection site

| Multiple                | 32 (29.1%)        | 42 (51.2%)      | 0.002 |
| Single                  | 78 (70.9%)        | 40 (48.8%)      |       |

Source of infection

| Respiratory tract       | 100 (90.9%)       | 70 (85.4%)      | 0.233 |
| Blood                   | 12 (10.9%)        | 15 (18.3%)      | 0.145 |
| Intracranial            | 6 (5.5%)          | 4 (4.9%)        | 1.000 |
| Urinary tract           | 7 (6.4%)          | 6 (7.3%)        | 0.795 |
| Digestive tract         | 2 (1.8%)          | 2 (2.4%)        | 1.000 |
| Abdomen                 | 13 (6.4%)         | 10 (6.1%)       | 0.940 |
| Skin/soft tissue        | 2 (1.8%)          | 1 (1.2%)        | 1.000 |

Underlying diseases

| Pulmonary disease       | 79 (71.8%)        | 61 (74.4%)      | 0.692 |
| Hypertension            | 35 (31.8%)        | 19 (23.2%)      | 0.187 |
| Diabetes mellitus       | 15 (13.6%)        | 12 (14.6%)      | 0.844 |
| Recent surgery          | 12 (10.9%)        | 5 (6.1%)        | 0.246 |
| Nervous system          | 39 (35.5%)        | 19 (23.2%)      | 0.067 |

Pathogenic bacteria

| Acinetobacter baumannii| 70 (63.6%)        | 51 (62.2%)      | 0.838 |
| Klebsiella pneumoniae  | 30 (27.3%)        | 19 (23.2%)      | 0.519 |
| Parameters                                                                 | Success (N = 110) | Failure (N = 82) | P       |
|---------------------------------------------------------------------------|-------------------|------------------|---------|
| **Pseudomonas aeruginosa**                                               | 18 (16.4%)        | 15 (18.3%)       | 0.726   |
| **Escherichia coli or Enterobacter cloacae**                             | 2 (1.8%)          | 5 (6.1%)         | 0.139   |
| Loading dose (N, %)                                                      | 43 (39.1%)        | 26 (31.7%)       | 0.292   |
| Loading dose (mg/d)                                                      | 50.0 (50.0–100.0) | 50.0 (50.0–100.0) | 0.477   |
| Maintenance dose (mg/d)                                                  | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 0.651   |
| Total cumulative dose (mg)                                               | 1100.0 (700.0–1443.8) | 800.0 (500.0–1112.5) | **0.001** |
| Dose per kg (mg/kg/q12h)                                                 | 0.87 (0.79–1.00)  | 0.86 (0.83–1.00)  | 0.541   |
| Daily PMB dose (mg)                                                      | 100.0 (100.0–100.0) | 100.0 (100.0–100.0) | 0.794   |
| **Administration**                                                       |                   |                  |         |
| Intravenous drip                                                         | 110 (100.0%)      | 81 (98.8%)       | 1.000   |
| Intrathecal injection                                                    | 3 (2.7%)          | 2 (2.4%)         | 1.000   |
| Injection                                                                | 0                 | 1 (1.2%)         | 0.427   |
| Inhalation                                                               | 6 (5.5%)          | 2 (2.4%)         | 0.470   |
| Starting PMB treatment after CRO confirmed (days)                        | 1.0 (0.0–4.0)     | 1.5 (0.0–3.8)    | 0.761   |
| Treatment duration (days)                                                | 11.0 (8.0–14.0)   | 8.0 (6.0–11.0)   | <0.001  |
| **Combination**                                                          |                   |                  |         |
| PMB alone                                                                | 7 (6.4%)          | 10 (12.2%)       | 0.159   |
| Meropenem                                                                | 40 (36.4%)        | 24 (29.3%)       | 0.302   |
| Tigecycline                                                              | 32 (29.1%)        | 31 (37.8%)       | 0.203   |
| Cefoperazone/sulbactam                                                   | 31 (28.2%)        | 22 (26.8%)       | 0.836   |

Data are reported as numbers (%), mean ± standard deviation or median values (interquartile ranges [IQR]), as appropriate. Bold font indicates data with significant differences.

We also created a multivariate logistic regression model for the clinical efficacy of PMB that incorporated use of mechanical ventilation and vasoactive agents, multiple-site infection, duration of PMB treatment (days), and total cumulative dose of PMB. After adjustments, use of mechanical ventilation (odds ratio =
3.043; 95% confidence interval: 1.253–7.389; \( P = 0.014 \)), vasoactive agents (2.560; 1.180–5.554; 0.017), multiple-site infection (1.280; 1.077–4.083; 0.001), and the total cumulative dose of PMB (1.001; 1.000–1.001; 0.037) were independently associated with the clinical efficacy of PMB (Table 4). Moreover, the results of Cox-regression survival analysis for 30-day mortality showed that the use of vasoactive agents (4.335; 1.006–18.685; 0.049) and the total cumulative dose of PMB (0.998; 0.996–0.999; 0.006) could influence survival time and mortality rate independently (Table 5). High cumulative dose was an independent protective factor, while the use of vasoactive drugs was an independent risk factor (Fig. 2).

| Variable                  | Adjusted OR | 95% CI          | \( P \) value |
|---------------------------|-------------|-----------------|---------------|
| Mechanical ventilation    | 3.043       | 1.253–7.389     | 0.014         |
| Vasoactive agents         | 2.560       | 1.180–5.554     | 0.017         |
| Multiple-site infection   | 1.280       | 1.077–4.083     | 0.001         |
| Total cumulative dose (mg)| 1.001       | 1.000–1.001     | 0.037         |
| Treatment duration (days) | 0.960       | 0.906–1.018     | 0.174         |

Bold font indicates data with significant differences.

| variable                  | Hazard ratio | 95% CI          | \( P \)       |
|---------------------------|--------------|-----------------|---------------|
| Mechanical ventilation    | 1.434 \times 10^5 | 0.000–7.251 \times 10^{133} | 0.937         |
| Vasoactive agents         | 4.335        | 1.006–18.685    | 0.049         |
| Multiple-site infection   | 1.907        | 0.873–4.165     | 0.105         |
| Total cumulative dose (mg)| 0.998        | 0.996–0.999     | 0.006         |
| Treatment duration (days) | 1.088        | 0.941–1.257     | 0.253         |

Bold font indicates data with significant differences.

### 3.4. Adverse effects

Overall, 22 cases (11.4%) suffered the adverse effects of PMB treatment. The most prevalent adverse effect was nephrotoxicity (eight cases; 4.2%), followed by nerve–muscle blockade (three cases; 1.6%) and skin hyperpigmentation (three cases; 1.6%). Moreover, some rare adverse effects occurred, including two cases of drug-induced fever, and drug-induced eruption, pruritus, nausea, general weakness, lethargy, and hepatotoxicity in one patient (Table 6).
Table 6
Adverse reactions following PMB therapy

| Adverse effects                  | Number (%) |
|----------------------------------|------------|
| Nephrotoxicity                   | 8 (4.2%)   |
| Nerve–muscle blockade            | 3 (1.6%)   |
| Skin hyperpigmentation           | 3 (1.6%)   |
| Drug-induced fever               | 2 (1.0%)   |
| Drug-induced eruption            | 1 (0.5%)   |
| Pruritus                         | 1 (0.5%)   |
| Nausea                           | 1 (0.5%)   |
| General weakness                 | 1 (0.5%)   |
| Lethargy                         | 1 (0.5%)   |
| Hepatotoxicity                   | 1 (0.5%)   |
| Total                            | 22 (11.4%) |

4. Discussion

CRO infections (especially CRE) represent an urgent threat because few drugs are available to treat infections caused by these pathogens. PMB is one of the “last resort” choices for CRO infections. Therefore, the factors that affect PMB efficacy must be clarified for its rational and efficacious application.

We wished to explore the factors affecting PMB efficacy. We enrolled 192 CRO-infected patients; 110 of these patients had CS after PBM treatment and 82 had CF after PBM treatment. PMB was more efficacious in patients who had a longer duration of treatment and a higher total cumulative dose. There was a linear association between treatment duration and total cumulative dose that correlated with CS. More patients in the CF group had mechanical ventilation and vasoactive agents than those in the CS group.

The results of the current study are different from past investigations on the dose and efficacy of PMB. [16–18] Elias et al. showed (in a retrospective study) that increasing the daily dose of PMB (≥ 200 mg/day) reduced in-hospital mortality, and that its benefits outweighed the risk of renal insufficiency.[16] Mortality after PMB treatment was associated with an inappropriate daily dose (< 15,000 units/kg/day) in critically ill patients according to a retrospective study conducted by Ismail et al.[17] An investigation on the association between the colistin dose taking into account body weight and microbiologic outcomes showed that higher doses led to better outcomes. [18] However, the exact relationship between the daily dose and efficacy of PMB was not discovered in our study. In the International Consensus Guidelines for
the Optimal Use of the Polymyxins published in 2019.[15] the recommended daily dose of PMB is 1.25–1.50 mg/kg (q12h), and a loading dose of 2.0–2.5 mg/kg is suggested. However, the median daily dose of PMB in our study was 0.86 mg/kg (q12h). Furthermore, the recommended dose given by the PMB manufacturer was 500,000–1000,000 IU divided into two administrations per day, and the median daily dose in our study was 1000,000 IU. Hence, the daily dose in our study was lower than that recommended in guidelines but in accordance with manufacturer instructions. Obviously, the recommended dose in the manufacturer instructions was lower than that in the guidelines. This different association of daily dose and efficacy may be attributed to the cutoff of 200 mg/day set explicitly in Elias’s study and the different evaluation method for efficacy and in-hospital mortality.[16] No scholars have reported on the relationship between the cumulative dose and efficacy of PMB. The total cumulative dose of PMB in patients in the CS group was higher than that in the CF group [1100.0 (700.0–1443.8) vs. 800.0 (500.0–1112.5) mg; P = 0.001]. High cumulative dose was an independent protective factor for 30-day mortality (0.998; 0.996–0.999; 0.006), however, which was inevitably related to the longer duration of treatment.

Few studies have demonstrated that the efficacy of PMB is related to treatment duration. One retrospective study suggested that prolonging the duration of direct hemoperfusion with PMB-immobilized fibers can improve the clinical efficacy of PMB in septic-shock patients.[19] No scholars have shown that mechanical ventilation and application of vasoactive agents influence the efficacy of PMB. At the same time, the use of mechanical ventilation and vasoactive agents also inevitably means that patients have more serious diseases. This may also be the cause of the different efficacy. However, PMB treatment has been shown to improve the prognosis of patients undergoing mechanical ventilation. [20, 21]

Studies on the timing of medication administration have yielded differing results. In a study on the timing of PMB administration in CRKP-infected patients, early administration of PMB was found to be beneficial for improving bacterial clearance and patient survival.[8] In our study, there was no statistical difference in the timing of PMB medication between different clinical effects. This may indicate that after the confirmation of CROs infection, the timing of PMB medication may not affect the clinical efficacy of PMB in the short term.

There was no difference in the combination rate of these drugs between the CF and CS groups. It could be seen that the combination of drugs in this study may not be one of the factors that cause the difference in clinical efficacy. Several studies have also shown that PMB efficacy is related to its combination with other drugs [22, 23] such as tigecycline and enrofloxacin, but we did not find this to be the case. The differences in these conclusions were associated with the choice of endpoint indicators. PMB, tigecycline, and ceftazidime/avibactam are important drugs in the treatment of CRO infections. An in vitro study showed that CRE was much more sensitive to PMB than tigecycline,[24] and that the efficacy of PMB and tigecycline combined was greater than that of PMB alone or tigecycline alone.[10, 25] The combination of PMB and ceftazidime has been demonstrated to have a synergistic effect on CRKP in vitro.[26]
The prevalence of total adverse effects was 11.4% in our study. The prevalence of nephrotoxicity was 4.2%, which is lower than that in the study by Mattos and colleagues (40.5%),[27] Oliveira and co-workers (26.8%),[28] and Agarwal and collaborators (11.8%).[6] PMB neurotoxicity is caused mainly by inhibition of acetylcholine in neuromuscular junctions and PMB reabsorption by renal-cell receptors, but the overall mechanism is not known.[29, 30] The reason for the low prevalence of nephrotoxicity may have been the relatively low dose of PMB used in our study. The prevalence of skin hyperpigmentation was 1.6% in our study, which is lower than that reported by Mattos and colleagues (8.1%).[27] The reasons for pigmentation/darkening of skin vary, but the most common reason is melanin production in skin cells (especially in dermal macrophages). [31]

Our study had four main limitations. First, biases could not be controlled completely because this was a retrospective study. Second, the objectivity of PMB efficacy as an endpoint was insufficient. Third, the study cohort was small. Finally, patients had various underlying diseases that would have affected PMB efficacy.

In the future, the factors that affect the efficacy and adverse reactions of PMB must be explored in depth. In addition, pharmacokinetic parameters should be investigated more deeply by measuring the drug concentration in blood to achieve individualized administration of PMB.

5. Conclusions

PMB is an option for patients with CRO infection. It had good efficacy and a low prevalence of adverse reactions in the present study. The total cumulative dose and duration of PMB treatment, mechanical ventilation, vasoactive agents, and multiple-site infection were factors associated with the clinical efficacy of PMB.

Abbreviations

CROs: Carbapenem-resistant organisms; PMB: Polymyxin B; CS: clinical success; CF: clinical failure; CREs: Enterobacteriaceae-resistant organisms; MIC: minimum inhibitory concentration.

Declarations

Availability of data and materials

Available.

Acknowledgments

This work was supported by the National Scientific Foundation of China (No. 81503166), Hunan Provincial Natural Science Foundation of China (2018JJ3718), WU JIEPING Medical Foundation
Conflicts of interest:

All authors report no conflicts of interest relevant to this article.

Author Contributions:

JQ and QL conceptualized and designed the study. GHL, HHZ, ZBOY, WQW, JJW, TTQ, and HY collected data. QQ, HL and HY analyzed the data. GHL, HY, JQ, and QL drafted the manuscript. All authors contributed to the revision and approved the final version of the manuscript.

References

1. Chamieh A, El-Hajj G, Zmerli O, Afif C, Azar E. Carbapenem resistant organisms: A 9-year surveillance and trends at Saint George University Medical Center. J Infect Public Health 2019.

2. Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP, Chakraborty T. Treatment Options for Carbapenem-Resistant Gram-Negative Infections. Dtsch Arztebl Int. 2018;115(20–21):345–52.

3. Stansly PG, Schlosser ME. Studies on Polymyxin: Isolation and Identification of Bacillus polymyxa and Differentiation of Polymyxin from Certain Known Antibiotics. J Bacteriol. 1947;54(5):549–56.

4. Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrobial agents and chemotherapy 2017, 61(3).

5. Zakuan ZD, Suresh K. Rational use of intravenous polymyxin B and colistin: A review. Med J Malaysia. 2018;73(5):351–9.

6. Aggarwal R, Dewan A. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17(1):15.

7. Rigatto MH, Falci DR, Zavascki AP. Clinical Use of Polymyxin B. Adv Exp Med Biol. 2019;1145:197–218.

8. Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–5.

9. Dubrovskaya Y, Chen TY, Scipione MR, Esaian D, Phillips MS, Papadopoulos J, Mehta SA. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2013;57(11):5394–7.

10. Satlin MJ, Kubit CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55(12):5893–9.
11. Pan S, Huang X, Wang Y, Li L, Zhao C, Yao Z, Cui W, Zhang G. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinetobacter baumannii: a retrospective cohort study. Antimicrobial resistance infection control. 2018;7:8.

12. Cai Y, Leck H, Tan RW, Teo JQ, Lim TP, Lee W, Chlebicki MP, Kwa AL. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study. Antibiotics (Basel) 2020, 9(8).

13. Anania MC, Miranda C, Vizioli MG, Mazzoni M, Cleris L, Pagliardini S, Manenti G, Borrello MG, Pierotti MA, Greco A. S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(10):E1591–600.

14. Dalyan CB, Topac T, Agca H, Saglam S, Efe K, Ener B. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates]. Mikrobiyol Bul. 2018;52(1):35–48.

15. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.

16. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–7.

17. Ismail B, Shafei MN, Harun A, Ali S, Omar M, Deris ZZ. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect. 2018;51(6):763–9.

18. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis. 2013;56(3):398–404.

19. Miyamoto K, Kawazoe Y, Kato S. Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study. J Intensive Care. 2017;5:19.

20. Komatsu M, Hachiya T, Takahashi H, Yoshikawa S, Honda T. Direct hemoperfusion with polymyxin B-immobilized fiber for the treatment of the acute exacerbation of idiopathic pulmonary fibrosis in patients requiring invasive mechanical ventilation. Respiratory investigation. 2017;55(5):318–22.

21. Koami H, Sakamoto Y, Miyasho T, Itami T, Tamura J, Ishizuka T, Kawamura Y, Nakamura K, Miyoshi K, Yamashita K. The effects of polymyxin B-immobilized fiber hemoperfusion on respiratory impairment in endotoxemic pigs. J Nippon Med Sch. 2014;81(3):130–8.
22. Guo W, Guo SC, Li M, Li LH, Qu Y. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report. Antimicrobial resistance infection control. 2018;7:22.

23. Alves PH, Boff RT, Barth AL, Martins AF. Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates. Diagn Microbiol Infect Dis. 2019;94(1):81–5.

24. Zhang R, Cai JC, Zhou HW, Nasu M, Chen GX. Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems. J Med Microbiol. 2011;60(Pt 12):1813–9.

25. Rao GG, Ly NS, Diep J, Forrest A, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48(3):331–6.

26. Manning N, Balabanian G, Rose M, Landman D, Quale J. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. Microb Drug Resist. 2018;24(1):35–9.

27. Mattos KPH, Gouvea IR, Quintanilha JCF, Cursino MA, Vasconcelos P, Moriel P. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment. J Clin Pharm Ther. 2019;44(3):415–9.

28. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis. 2009;65(4):431–4.

29. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med. 1973;56(1):31–5.

30. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother. 2013;57(12):6319–24.

31. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253–62.